Premium
Managing children with chronic myeloid leukaemia ( CML )
Author(s) -
Fuente Josu,
Baruchel André,
Biondi Andrea,
Bont Eveline,
Dresse MarieFrançoise,
Suttorp Meinolf,
Millot Frédéric
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12977
Subject(s) - chronic myeloid leukaemia , medicine , minimal residual disease , bone marrow transplantation , transplantation , tyrosine kinase , myeloid , incidence (geometry) , disease , myeloid leukaemia , immunology , bone marrow , oncology , pediatrics , receptor , physics , optics
Summary Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that in adults. Significant advances in targeted therapy with the development and use in children of tyrosine kinase inhibitors and the ability to monitor and understand the prognostic significance of minimal residual disease by standardized molecular techniques has shifted the management of this condition from bone marrow transplantation as the main therapeutic modality to individualized treatment for each patient based on achieving specific milestones. The physiological changes occurring during childhood, particularly those affecting growth and development and the long‐term use of treatment, pose specific challenges in this age group, which we are only beginning to understand.